Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 fixed-sequence drug-drug interaction study of inarigivir with midazolam in healthy adults
NL-OMON46790Phase 1Active, not recruiting
- Sponsor
- Spring Bank Pharmaceuticals, Inc.
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of inarigivir and midazolam in Chronic Hepatitis B (CHB), sponsored by Spring Bank Pharmaceuticals, Inc. Primary endpoint: Effect of steady-state oral inarigivir on single-dose midazolam pharmacokinetics. Started May 2018; status: active, not recruiting.
02
Drugs
inarigivirmidazolam
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NL-OMON46790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46790.